尿水通道蛋白2或可预测托伐普坦治疗ADPKD的疗效
这项单中心前瞻性观察队列研究纳入92例接受托伐普坦治疗的常染色体显性多囊肾病(ADPKD)患者,发现治疗1个月时尿水通道蛋白2与尿肌酐比值(U-AQP2/Cr)较基线下降,且该初始变化与总肾脏体积(TKV)和估算肾小球滤过率(eGFR)的年变化率强烈相关,提示其可能作为托伐普坦治疗期间肾脏预后的指标。
要点
- 托伐普坦治疗1个月后U-AQP2/Cr从67.8降至20.7 fmol/mg尿肌酐。
- U-AQP2/Cr初始变化与TKV及eGFR的年变化率强烈相关。
- 初始U-AQP2/Cr下降反映托伐普坦药理作用,或可预测肾脏预后。
核心结论
- 托伐普坦治疗首月U-AQP2/Cr的初始下降反映其药理效应,可能作为治疗期间肾脏预后的指标。
研究设计与样本
- 单中心、前瞻性观察性队列研究,纳入92例接受托伐普坦治疗的ADPKD患者。
- 观察期2.4 ± 1.5年,采用单变量和多变量多元回归分析U-AQP2变化与临床参数及肾脏预后因素的相关性。
主要发现
- U-AQP2/Cr在托伐普坦治疗1个月后从67.8 ± 50.6降至20.7 ± 15.1 fmol/mg尿肌酐。
- U-AQP2/Cr初始变化与高基线U-AQP2/Cr、低基线eGFR及eGFR初始变化大相关。
- 多变量分析显示U-AQP2/Cr初始变化与TKV和eGFR的年变化率强烈相关。
临床怎么用
- 对接受托伐普坦治疗的ADPKD患者,可监测治疗首月U-AQP2/Cr下降幅度以辅助评估肾脏预后。
局限性
- 单中心、观察性设计,样本量有限,结果需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Tolvaptan is used to treat autosomal dominant polycystic kidney disease (ADPKD) because it inhibits binding of the antidiuretic hormone vasopressin to the vasopressin V2 receptor (V2R), which suppresses the insertion of preformed water channel aquaporin 2 (AQP2) molecules in the luminal membrane of the collecting duct cells. METHODS: This single-center, prospective observational cohort study investigated whether decreased AQP2 elimination in urine affects the renal prognosis of patients who received tolvaptan. We selected 92 patients with ADPKD who were administered tolvaptan in our hospital. We evaluated correlations between changes in urinary AQP2 (U-AQP2) and clinical parameters and the annual change in total kidney volume (TKV) and estimated glomerular filtration rate (eGFR) as renal prognostic factors using univariable and multivariable multiple regression analyses. RESULTS: The observation period was 2.4 ± 1.5 years. U-AQP2 per milligram of urinary creatinine (U-AQP2/Cr) decreased from 67.8 ± 50.6 to 20.7 ± 15.1 fmol/mg urinary creatinine after 1 month of tolvaptan treatment. This initial change in U-AQP2/Cr was correlated with high baseline U-AQP2/Cr, low baseline eGFR, and a large initial change in eGFR (baseline to 1 month). The initial change in U-AQP2/Cr (baseline to 1 month) was strongly correlated with the annual change in TKV and eGFR in multivariable analysis. CONCLUSION: Initial decrease in U-AQP2/Cr in the first month of treatment reflects the pharmacologic effect of tolvaptan and could be an indicator of renal prognosis during tolvaptan treatment.
引用
- Makabe S, Manabe S, Kataoka H, et al. Urinary Aquaporin 2 as a Potential Indicator Predicting Tolvaptan Response in Patients With ADPKD. Kidney Int Rep. 2021. PMID: 34514204. doi:10.1016/j.ekir.2021.06.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。